increase vulnerability to myalgias and contribute to the myopathic component often experienced with back pain, the objective of this study was to examine the association of statin use with the risk of back disorder diagnoses. Our a priori hypothesis was that statin use would be associated with back disorders, including spondylosis and intervertebral disc disorders.
Methods | We retrieved health care data for patients enrolled in TRICARE, the health insurance system of the US Department of Defense, in the San Antonio military area from October 1, 2003 , to March 1, 2012. 5 Inclusion criteria were being older than 30 years and having at least 1 medical encounter during the baseline period (2 years before the index date) and the follow-up period (starting 90 days after the index date through March 1, 2012, except for nonusers who were subsequently prescribed statins and for whom follow-up was censored at the date they filled their statin prescription). 5 Two treatment groups were identified: (1) statin users who recently received a first-time prescription for a statin and continued its use for 120 days or more and (2) statin nonusers who never used statins as well as statin users prior to being prescribed statins. 5 Prevalent statin users were excluded. This study was approved by the institutional review boards of Brooke Army Medical Center and the VA North Texas Health System. Patient informed consent was waived by both institutional review boards because the data were deidentified before being forwarded to the investigators. Data analyses were performed between February 23, 2016, and August 8, 2016. Our outcome was an occurrence of disease category 205 for back disorders (eg, spondylosis, intervertebral disc disorders, and other back problems), as listed in the Agency for Healthcare Research and Quality's Clinical Classifications Software (based on the International Classification of Diseases, Ninth Revision, Clinical Modification codes). 5 We created a PS using 115 baseline characteristics and matched treatment groups in a 1:1 ratio for the nearest neighbor (caliper of 0.01). 5 Primary analyses used conditional logistic regression analysis to examine the odds ratio (OR) of outcomes in the PS-matched cohort. We also calculated the number needed to harm. Abbreviations: FY, fiscal year; NSAIDs, nonsteroidal anti-inflammatory drugs. a Complete description of all baseline characteristics, including standardized mean differences, was previously published. 5 Patients were matched on all baseline characteristics included in the propensity score. 
Letters
Secondary analyses examined the OR of outcomes in the overall cohort (all patients identified before PS matching) and in several prespecified cohorts. Baseline characteristics for treatment groups were examined using χ 2 test to compare categorical variables and 2-tailed t test for continuous variables. Standardized differences were also calculated. Comparisons of outcomes, using conditional logistic regression, were considered statistically significant at P < .05. Statistical analyses were performed using SPSS software version 23 (IBM). Statin users in the PS-matched cohort had a higher likelihood of back disorders (OR, 1.27; 95% CI, 1.19-1.36). The number needed to be exposed for an additional harm was 17. 6 All secondary analyses showed similar results, including analyses of longer use and higher intensity of statin ( Table 2) .
Discussion | In this study, statin use was associated with increased likelihood of back disorder diagnoses and a dose response to both dosage and duration. To our knowledge, this study is the first to report greater odds of back disorders among statin users compared with the odds of nonusers in a population with equal access to and the same cost of health care. Few studies have examined the association of statins with back pain. In a cross-sectional study of statin users vs nonusers, statin users had higher adjusted OR of lower back pain (OR, 1.59; 95% CI, 1.04-2.44). 4 In another study, among those without arthritis, statin users had a higher adjusted prevalence ratio of lower back pain. 3 Limitations of this study include its retrospective nature and the use of Clinical Classifications Software codes. Because the study participants were TRICARE enrollees, these results may not be generalizable to a more sedentary population or to those without exposure to military or veteran experience.
Our results provide additional motivation to further investigate the overall influence of statin therapy on musculoskeletal health, specifically if prescribed for primary prevention in physically active individuals. Medications were included that may be associated with increased body weight or musculoskeletal symptoms (eg, systemic corticosteroids, selective serotonin reuptake inhibitors, antipsychotic, bisphosphonate, hormone replacement therapy, testosterone, warfarin, and cytochrome P450 inhibitors). Invasive revascularization procedures (percutaneous coronary intervention, coronary artery bypass surgery, or peripheral revascularization procedure) were assumed to result in prolonged bed rest and hospitalization; hence, it may contribute to musculoskeletal symptoms. e High-intensity statin was defined by the 2013 guidelines of the American College of Cardiology/American Heart Association for cholesterol management, with modification to include simvastatin, 80 mg, as high-intensity statin. High-intensity statin users used these medications for 120 days or more. f Nonobese cohort excluded patients diagnosed with obesity at baseline or at follow-up. g Healthy cohort excluded patients with any component of the Charlson comorbidity index or other severe comorbidities, as previously described. The emergency department and hospital discharge diagnoses are not necessarily the same. We included patients if their primary diagnosis was syncope in either the emergency department or at hospital discharge, using the ICD-10 code R55. We excluded patients who were receiving anticoagulation at admission, had prior syncope, or were pregnant. The main outcomes were the occurrence of investigation for venous thromboembolism (VTE) during hospitalization, defined as testing with a plasma D-dimer level, compression ultrasonography of the upper or lower limbs, computed tomographic pulmonary angiography (CTPA), or ventilation perfusion (V/Q) scan, and the diagnostic yield of these investigations. Because there is substantial overlap in the investigation and management of DVT and PE, we examined a composite of all investigations for VTE. The GEMINI study received research ethics board approval from all participating hospitals.
Results | Of the 1650 patients hospitalized with syncope, 345 were excluded (179 with preadmission anticoagulation and 166 with previous syncope), and the final cohort included 1305 patients. At least 1 investigation for VTE was performed in 146 patients (11.2% [95% CI, 9.6%-13.0%]) ( Table 1) , including 120 who received imaging with CTPA, V/Q scan, and/or compression ultrasonography (9.2% [95% CI, 7.8%-10.9%]).
Pulmonary embolism was diagnosed in 11 of the 73 patients who received a CTPA or V/Q scan, and DVT was diagnosed in 10 of the 67 patients who received ultrasonography, representing a diagnostic yield of 15.1% (95% CI, 8.6%-25.0%) and 14.9% (95% CI, 8.3%-25.4%), respectively. The prevalence of VTE in the cohort was 1.4% (95% CI, 0.9%-2.2%) ( Table 2) .
Discussion | In a large observational study, VTE was investigated in 11.2% of patients hospitalized with syncope. The diagnostic yield for VTE was 15.0% and the prevalence was 1.4%, not 41.9% and 17.1%, respectively, as found in the PESIT study. 1 Our findings call into question the generalizability of the PESIT results. The 1.4% prevalence of VTE we found is consistent with previously published estimates, which range from 0.9% to 2.8%. [2] [3] [4] Unlike the case in PESIT, all patients were not screened for VTE in our study or in these previous studies; thus, the prevalence may have been underestimated. A more illuminating comparison, however, is to examine the diagnostic yield of imaging for VTE. We expected that thrombosis would be
